JP2021524864A5 - - Google Patents
Info
- Publication number
- JP2021524864A5 JP2021524864A5 JP2021514303A JP2021514303A JP2021524864A5 JP 2021524864 A5 JP2021524864 A5 JP 2021524864A5 JP 2021514303 A JP2021514303 A JP 2021514303A JP 2021514303 A JP2021514303 A JP 2021514303A JP 2021524864 A5 JP2021524864 A5 JP 2021524864A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025014460A JP2025084741A (ja) | 2018-05-15 | 2025-01-31 | 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671466P | 2018-05-15 | 2018-05-15 | |
| US201862671485P | 2018-05-15 | 2018-05-15 | |
| US62/671,466 | 2018-05-15 | ||
| US62/671,485 | 2018-05-15 | ||
| US201862674855P | 2018-05-22 | 2018-05-22 | |
| US62/674,855 | 2018-05-22 | ||
| PCT/US2019/032403 WO2019222339A1 (en) | 2018-05-15 | 2019-05-15 | Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025014460A Division JP2025084741A (ja) | 2018-05-15 | 2025-01-31 | 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021524864A JP2021524864A (ja) | 2021-09-16 |
| JP2021524864A5 true JP2021524864A5 (enExample) | 2022-11-02 |
| JP7699378B2 JP7699378B2 (ja) | 2025-06-27 |
Family
ID=68541027
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514303A Active JP7699378B2 (ja) | 2018-05-15 | 2019-05-15 | 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法 |
| JP2025014460A Pending JP2025084741A (ja) | 2018-05-15 | 2025-01-31 | 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025014460A Pending JP2025084741A (ja) | 2018-05-15 | 2025-01-31 | 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11090303B2 (enExample) |
| EP (1) | EP3843768A4 (enExample) |
| JP (2) | JP7699378B2 (enExample) |
| CN (1) | CN112423774A (enExample) |
| AU (1) | AU2019271189A1 (enExample) |
| BR (1) | BR112020023252A2 (enExample) |
| GB (1) | GB202015788D0 (enExample) |
| MA (1) | MA53500A (enExample) |
| WO (1) | WO2019222339A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53500A (fr) | 2018-05-15 | 2021-08-18 | Lloyd Hung Loi Tran | Composition d'agent thérapeutique et procédé d'utilisation, pour le traitement d'un trouble cognitif léger, de la dépression et de troubles psychologiques |
| US20240398792A1 (en) * | 2018-05-15 | 2024-12-05 | Lloyd Hung Loi Tran | Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease |
| CA3179317A1 (en) | 2020-04-20 | 2021-10-28 | Lloyd Hung Loi TRAN | Methods for the prophylaxis and treatment of covid and covid-19 |
| WO2022051631A1 (en) | 2020-09-03 | 2022-03-10 | University Of Notre Dame Du Lac | Therapy to stimulate hippocampal neural progenitors and adult neurogenesis |
| IL305132A (en) * | 2021-02-12 | 2023-10-01 | Neuren Pharmaceuticals Ltd | Preparations for the treatment of the Prader-Willi phenomenon |
| CN114582507A (zh) * | 2022-03-04 | 2022-06-03 | 青海省畜牧兽医科学院 | 基于地理探测器的泡型包虫病环境风险因子分析方法 |
| KR20260049797A (ko) * | 2023-07-12 | 2026-04-14 | 로이드 트란 | 경도 인지 장애 치료를 위한 병용 요법의 치료제 조성물 및 사용 방법 |
| WO2025088052A1 (en) * | 2023-10-26 | 2025-05-01 | Rousselot Bv | Cyclic analogue of glycine-proline for use in the prevention and/or treatment of medical implant-related fibrosis |
| WO2025160184A1 (en) * | 2024-01-23 | 2025-07-31 | Lloyd Tran | Methods for the prophylaxis and treatment of obesity and related conditions and disorders |
| WO2025179250A1 (en) * | 2024-02-25 | 2025-08-28 | Lloyd Tran | Methods for the prophylaxis and treatment of autism related disorders |
| WO2025198995A1 (en) * | 2024-03-18 | 2025-09-25 | Lloyd Tran | Methods for the prophylaxis and treatment of stroke related disorders |
| WO2026112551A1 (en) * | 2024-11-24 | 2026-05-28 | Lloyd Tran | Methods for the prophylaxis and treatment of substance use disorder (sud) including but not limited to alcohol use disorder (aud) |
| CN119770491B (zh) * | 2024-12-20 | 2025-10-17 | 北京大学 | 环甘氨酸-脯氨酸在制备治疗暴食症的药物中的应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2670563B2 (ja) | 1988-10-12 | 1997-10-29 | 富士通株式会社 | 半導体装置の製造方法 |
| JP2757960B2 (ja) | 1988-10-17 | 1998-05-25 | サントリー株式会社 | （２Ｒ，３Ｓ，４Ｓ）−α−（カルボキシシクロプロピル）グリシン |
| SE8803847A0 (sv) | 1988-10-27 | 1990-04-28 | Kabigen Ab | Neuromodulerande peptid |
| ES2101865T3 (es) | 1991-08-01 | 1997-07-16 | Genentech Inc | Igf-1 para mejorar el estado neural. |
| US5439930A (en) | 1992-04-14 | 1995-08-08 | Russian-American Institute For New Drug Development | Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects |
| CA2178711A1 (en) | 1993-12-23 | 1995-06-29 | Peter David Gluckman | Composition and methods to improve neural outcome |
| US5840736A (en) | 1996-11-13 | 1998-11-24 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5942422A (en) | 1996-11-14 | 1999-08-24 | The Trustees Of Columbia University In The City Of New York | Method for generating a directed, recombinant fusion nucleic acid |
| US6015786A (en) | 1997-02-25 | 2000-01-18 | Celtrix Pharmaceuticals, Inc. | Method for increasing sex steroid levels using IGF or IGF/IGFBP-3 |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| US6187906B1 (en) | 1997-08-11 | 2001-02-13 | Aukland Uniservices Limited | Methods to improve neural outcome |
| US6124361A (en) | 1997-12-31 | 2000-09-26 | Pfizer Inc | Bicyclo[3.1.0]hexanes and related compounds |
| IL138342A0 (en) | 1998-03-17 | 2001-10-31 | Pfizer Prod Inc | Bicyclo[2.2.1] heptanes and related compounds |
| US6258582B1 (en) | 1998-09-30 | 2001-07-10 | Millennium Pharmaceuticals, Inc. | CSAPTP nucleic acid molecules and uses therefor |
| US6303576B1 (en) | 1999-04-21 | 2001-10-16 | Adherex Technologies Inc. | Compounds and methods for modulating β-catenin mediated gene expression |
| KR20020079731A (ko) | 1999-11-05 | 2002-10-19 | 액소닉스, 인코포레이티드. | 아밀로이드, 아밀로이드-유사 침착물, 또는 β-쉬이트가풍부한 그의 병리학적 전구체로의 비정상적 단백질 폴딩과관련된 질환의 치료에 있어서 생체내에서 사용하기에적합한 펩티드 동족체 및 유사체 |
| US6689904B2 (en) | 2001-06-29 | 2004-02-10 | Wyeth | Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine |
| AU2002340465A1 (en) | 2001-11-09 | 2003-05-19 | Neuronz Biosciences, Inc. | Cyclo(prolyl-glycine) and methods of use to treat neural disorders |
| US20100247483A1 (en) * | 2001-11-13 | 2010-09-30 | Tran Loi H | Therapeutic agent composition and method of use |
| CA2466701C (en) * | 2001-11-13 | 2013-11-12 | Loi Tran | Neuroprotective use of cyclic prolyl glycine |
| US7232798B2 (en) | 2001-11-13 | 2007-06-19 | Tran Loi H | Neuroprotection and neuroegenisis by administering cyclic prolyl glycine |
| US20050209142A1 (en) | 2002-11-20 | 2005-09-22 | Goran Bertilsson | Compounds and methods for increasing neurogenesis |
| US6969702B2 (en) | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
| EP1664050B1 (en) * | 2003-09-03 | 2015-12-09 | Neuren Pharmaceuticals Limited | Neuroprotective bicyclic compounds and pharmaceutical compositions containing them |
| US8791117B2 (en) * | 2003-09-03 | 2014-07-29 | Neuren Pharmaceuticals Limited | Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals |
| EP1870097A1 (en) * | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| US8263547B2 (en) | 2008-05-28 | 2012-09-11 | Massachusetts Institute Of Technology | DISC-1 pathway activators in the control of neurogenesis |
| US20110288011A1 (en) | 2008-12-05 | 2011-11-24 | Jean-Paul Castaigne | Peptide therapeutic conjugates and uses thereof |
| SI3024463T1 (sl) * | 2013-07-25 | 2020-08-31 | Neuren Pharmaceuticals Limited | Nevroprotektivne biciklične spojine in postopki za njihovo uporabo pri zdravljenju motenj avtističnega spektra in nevrorazvojnih motenj |
| EP3551354B1 (en) * | 2018-02-19 | 2021-09-08 | The Material Works, Ltd. | Width and speed control for sheet metal descaler and methods of using same |
| MA53500A (fr) | 2018-05-15 | 2021-08-18 | Lloyd Hung Loi Tran | Composition d'agent thérapeutique et procédé d'utilisation, pour le traitement d'un trouble cognitif léger, de la dépression et de troubles psychologiques |
-
2019
- 2019-05-15 MA MA053500A patent/MA53500A/fr unknown
- 2019-05-15 EP EP19804060.2A patent/EP3843768A4/en active Pending
- 2019-05-15 BR BR112020023252-1A patent/BR112020023252A2/pt not_active IP Right Cessation
- 2019-05-15 GB GBGB2015788.9A patent/GB202015788D0/en not_active Ceased
- 2019-05-15 CN CN201980047677.1A patent/CN112423774A/zh active Pending
- 2019-05-15 JP JP2021514303A patent/JP7699378B2/ja active Active
- 2019-05-15 US US16/412,759 patent/US11090303B2/en active Active
- 2019-05-15 AU AU2019271189A patent/AU2019271189A1/en not_active Abandoned
- 2019-05-15 WO PCT/US2019/032403 patent/WO2019222339A1/en not_active Ceased
-
2021
- 2021-06-26 US US17/359,515 patent/US20220000866A1/en not_active Abandoned
-
2023
- 2023-05-11 US US18/315,910 patent/US12070458B2/en active Active
-
2025
- 2025-01-31 JP JP2025014460A patent/JP2025084741A/ja active Pending